Table II.
Univariate and multivariate analyses of clinicopathological factors affecting lymph node metastasis.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Factors | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age (<50/≥51) | 0.97 | 0.48–1.97 | 0.93 | – | – | – |
| T stage (T1/T2-3) | 2.69 | 1.30–5.79 | <0.01 | 1.91 | 0.77–4.87 | 0.164 |
| LI (absent/present) | 19.51 | 7.57–61.01 | <0.01 | – | – | – |
| VI (absent/present)) | 9.97 | 4.48–23.92 | <0.01 | 9.22 | 3.90–23.66 | <0.001 |
| ER (absent/present) | 1.60 | 0.58–5.16 | 0.39 | – | – | – |
| PgR (absent/present) | 0.92 | 0.41–2.10 | 0.84 | – | – | – |
| HER2 (absent/present) | 1.51 | 0.55–3.95 | 0.41 | – | – | – |
| Recurrence | 3.90 | 1.54–10.27 | <0.01 | 2.54 | 0.81–8.33 | 0.113 |
| KIF18A (low/high) | 2.05 | 1.01–4.21 | 0.047 | 3.20 | 1.34–8.09 | 0.010 |
LI, lymphatic invasion; VI, venous invasion; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; KIF18A, kinesin family member 18A; HR, hazard ratio; CI, confidence interval.